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ABSTRACT
Background: Glioma accounts for the majority of primary malignant brain tumors
in adults.
Methods: Glioma specimens and normal brain tissues were analyzed for the
expression levels of GSK-3β and p-GSK-3β (Ser9) by tissue microarray analysis (TMA)
and Western blotting. Glioma cells over-expressing GSK-3β were used to analyze
biological functions both in vitro and in vivo.
Results: The levels of p-GSK-3β (Ser9), but not total GSK-3β, are significantly
up-regulated in glioma tissues compared to normal tissues, and are significantly
correlated with the glioma grades. Ectopic expression of GSK-3β decreased the
phosphorylation levels of mTOR and p70S6K1; and inhibited β-catenin, HIF-1α and
VEGF expression. Forced expression of GSK-3β in glioma cells significantly inhibited
both tumor growth and angiogenesis in vivo.
Conclusions: These results reveal that GSK-3β regulates mTOR/p70S6K1
signaling pathway and inhibits glioma progression in vivo; its inactivation via p-GSK3β (Ser9) is associated with glioma development, which is new mechanism that may
be helpful in developing GSK-3β-based treatment of glioma in the future.

only improved from 10 to 14 months after diagnosis
[1, 2]. One of the special characters of glioma is wellperfused blood vessel with very high density in the
brain, which is different from many other types of
cancers. Angiogenesis is the formation of new blood
vessels out of the pre-existing vasculature, and is vital
for tumorigenesis and tumor development [3]. Glioma
usually manifests itself as a focal lesion with central

INTRODUCTION
Gliomas are the most aggressive types of primary
intracranial tumors and constitute almost 80% of
primary brain tumors. In the last 5 years, despite with
the improvement of some treatments, such as aggressive
surgery, radiation and chemotherapies, the median
survival (MS) rate of patients with malignant glioma
www.impactjournals.com/oncotarget
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necrosis surrounded by an angiogenic tumor rim (one of
the characteristics of GBM); this type of tumor invades
the surrounding extracellular matrix, using both white
matter tracts and blood vessels as substrates. Extensive
studies have confirmed that angiogenesis is required for
malignant glioma growth [4, 5].
GSK-3 is a multifunctional Ser/Thr kinase,
which was first identified as a critical mediator in
glycogen metabolism and insulin signaling [6, 7]. It is
now known that GSK-3 is an important component of
diverse signaling pathways involved in the regulation
of protein synthesis, glycogen metabolism, cell
mobility, proliferation and survival [8, 9]. There are
two mammalian GSK-3 isoforms encoded by distinct
genes: GSK-3a and GSK-3β, which share 85% identity
[10]. Despite a high degree of similarity and functional
overlap, these isoforms are not functionally identical and
redundant. It is now known that GSK-3β plays a central
role in a variety of signaling pathways, such as the
Wnt/β-catenin, Hedgehog, Notch and insulin signaling
pathways [11–15]. Accordingly, GSK-3β activity
depends on the balance of phosphorylation levels at
activating Tyr216 site and inactivating Ser9 site levels.
A number of kinases can phosphorylate its N-terminal
serine-9 residue, including AKT and mitogen-activated
protein kinase (MAPK)-1, leading to the auto-inhibition
of GSK-3β. The dysregulation of GSK-3β has also been
implicated in tumorigenesis and cancer progression [8,
11, 16–18]. However, the role of GSK-3β and GSK-3β
Ser9 phosphorylation in glioma development is unclear,
and the mechanisms underlying GSK-3β regulation
of neoplastic transformation and tumor development
remains to be elucidated.
In this study, we applied tissue microarray technique
to detect a significant increase of p-GSK3β-Ser-9 levels
in most glioma tissues, which is associated with patients
with high-grade gliomas and metastatic tumors. Moreover,
overexpression of GSK-3β inhibited angiogenesis and
tumor growth in vivo. These studies elucidate the specific
role of GSK-3β in glioma, and helped further determine
the underlying mechanism of GSK-3β in regulating
glioma development.

relative expression levels of GSK-3β and p-GSK-3β
(Ser9) were analyzed by two experienced pathologists
in a blind manner and marked as final IHC scores: 0
(negative), + (weak), ++ (moderate) and +++ (strong).
Types of tissues used are listed in Table 1. Higher
p-GSK-3β (Ser9) expression levels were detected in
60 (67%) of 90 glioma cases, and were significantly
correlated with higher glioma grade (Figure 1B). There
was no significant correlation between total expression
levels of GSK-3β with the glioma grade and normal
tissue specimens (Figure 1B). We further analyzed the
expression levels of GSK-3β and p-GSK-3β (Ser9) in
5 normal brain tissues and 33 glioma specimens by
Western blotting assay. Pathologic features of tissue
samples are listed in Table 2. Consistent with the
results in TMA, the expression levels of p-GSK-3β
(Ser9), but not total GSK-3β, were greatly increased
in glioma tissues, and were positively correlated with
higher glioma grades (Figure 1C, and 1E). Since GSK3β is the initiation step of proteasome-dependent
degradation of β-catenin, we also examined levels of
β-catenin in glioma tissues. As shown in Figure 1C and
1F, the levels of β-catenin expression in glioma tissues
were significantly increased compared with normal
tissues, and higher grades of glioma are associated with
higher expression levels of β-catenin. These results
indicated that p-GSK-3β (Ser9) plays an important role
in increasing β-catenin expression and is a potential
biomarker of glioma development.

GSK-3β inhibits β-catenin and mTOR/p70S6K1
signal pathways, and down-regulates HIF-1 and
VEGF expression
To understand the mechanism of GSK-3β in
regulating glioma development, human glioma cell lines
U87 and U251 were infected with the adenovirus carrying
GSK-3β cDNA (Ad-GSK-3β) or GFP control (Ad-GFP).
The expression levels of GSK-3β were analyzed in these
cell lines U87-GFP, U87-GSK-3β, U251-GFP, U251GSK-3β by Western blotting. As shown in Figure 2A and
2B, expression levels of GSK-3β were similar in mock
cells and GFP cells, whereas GSK-3β levels were greatly
increased in GSK-3β-overexpressing U87 and U251 cells.
This result demonstrated that these adenovirus infected
cells successfully overexpress GSK-3β. To identify
signaling pathways that may be regulated by GSK-3β,
we demonstrate that delivery of exogenous GSK-3β
attenuated the expression levels of β-catenin (Figure
2A and 2B) and decreased the phosphorylation levels of
mTOR and p70S6K1 (Figure 2C and 2D). No significant
differences were found in the levels of total mTOR and
p70S6K1 in any of the cells. MTOR/p70S6K1 signaling
pathway is known to be involved in regulation of HIF-1α
stability [21]. Overexpression of GSK-3β is sufficient to

RESULTS
Increase of GSK-3β phosphorylation levels at
Serine 9 in glioma tissues
The expression levels of GSK-3β and p-GSK3β (Ser9) in 9 normal tissue specimens and 90 glioma
tissues of paraffin-embedded formalin-fixed were
detected by Tissue Microarray Analysis (TMA). The
results showed that the expression levels of p-GSK3β (Ser9) are significantly up-regulated in glioma
tissues compared with normal tissues (Figure 1A). The
www.impactjournals.com/oncotarget
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Figure 1: Human glioma tissues express high levels of p-GSK-3β (Ser9). A. The expression levels of GSK-3β and p-GSK-3β

(Ser9) in normal brain tissues and four (I, II, III, IV) grades of glioma tissues were analyzed by human tissue mircroarry, bar 40 μm. B.
Relative expression levels of GSK-3β and p-GSK-3β (Ser9) in human normal brain tissues and four grades of glioma tissues were analyzed
by two experienced pathologists in a blind manner and marked as final IHC scores; P value represents the difference of GSK-3β and
p-GSK-3β (Ser9) expression levels between normal brain tissues and four grades of gliomas sections. (Continued)
www.impactjournals.com/oncotarget
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Figure 1: (Continued) Human glioma tissues express high levels of p-GSK-3β (Ser9). C. Levels of GSK-3β, p-GSK-3β

(Ser9) and β-catenin in human normal brain tissues and four grade gliomas tissues were determined by Western blotting; 20 μg of
protein extracts from U87 cells was used, and β-tubulin was used as an internal loading control. D, E. and F. Relative densities were
quantified using ImageJ software. Results are presented as mean ± SD from three duplicates. Asterisk indicates significant difference
when compared to the control (P < 0.05).

decrease HIF-1α level (Figure 2E). It was reported that
VEGF is regulated by HIF-1α through hypoxia responsive
element [22]. Here we demonstrate that GSK-3β
inhibits VEGF mRNA and protein levels by RT-PCR
www.impactjournals.com/oncotarget

and ELISA assay (Figure 2F and 2G). These results
showed that ectopic expression of GSK-3β decreased the
phosphorylation of mTOR and p70S6K1; and inhibited
β-catenin, HIF-1α and VEGF expression.
31904
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Table 1 and 2: The information of human brain tissues (types and WHO criteria) was summarized
in Table I and II
I
Type of tissues

WHO grade

Normal brain tissue

Number of cases
9

Pilocytic astrocytoma

I

18

Diffuse astrocytoma

II

9

Oligoastrocytoma

II

15

Oligodendroglioma

II

11

Anaplastic gliomas

21

Anaplastic astrocytoma

III

7

Anaplastic oligoastrocytoma

III

7

Anaplastic oligodendroglioma

III

7

Glioblastoma multiforme

IV

16

WHO grade

Number of cases

II
Type of tissues
Normal brain tissue

5

Low-grade gliomas

6

Pilocytic astrocytoma

I

2

Diffuse astrocytoma

II

1

Oligoastrocytoma

II

2

Oligodendroglioma

II

1

Anaplastic gliomas

5

Anaplastic astrocytoma

III

2

Anaplastic oligoastrocytoma

III

2

Anaplastic oligodendroglioma

III

1

Glioblastoma multiforme

IV

6

GSK-3β inhibits tumor angiogenesis in vivo

GSK-3β expression suppresses tumor growth
in vivo

HIF-1α/VEGF pathway is a major angiogenesis
signaling pathway in both physiological and pathological
processes [23]. To examine the potential roles of GSK3β in angiogenesis, we performed angiogenesis assay
in vivo. U87-GSK-3β cells were trapped in growth factorfree Matrigel, and implanted into both flanks of nude
mice. Uninfected and U87-GFP cells were used as the
negative control. U87 cells induced angiogenesis, which
was inhibited by GSK-3β-overexpression (Figure 3A).
The hemoglobin levels in the plugs were used to evaluate
angiogenesis responses. Ectopic expression of GSK-3β
decreased hemoglobin levels by 35% compared to the
GFP group (Figure 3B). These results demonstrate that
GSK-3β inhibit tumor-induced angiogenesis.
www.impactjournals.com/oncotarget

Angiogenesis is required for tumor growth and
metastasis. To further determine whether GSK-3β activation
in U87 is sufficient in inhibiting tumor growth, we generated
xenograft tumors by the injection of U87-GSK-3β or U87GFP control cells subcutaneously into nude mice for 35
days. As shown in Figure 4A, the sizes of tumors from GSK3β-expressing cells were much smaller than those from the
GFP control group after 5 weeks of the injection. GSK-3β
overexpression decreased tumor growth by 65% compared to
the Ad-GFP group (Figure 4B). Then, representative sections
of the tumors were stained using monoclonal antibody against
CD31. Consistent with the results in angiogenesis assay, the
immunohistochemical analysis indicated that there were a
31905
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Figure 2: Overexpression of GSK-3β attenuated β-catenin and mTOR/p70S6K1 activation in human glioma cells.

A. U87 and U251 cells were transfected with or without adenovirus carrying GSK-3β or GFP at 10 MOI. After transfection for 48 h,
the expression levels of GSK-3β, β-catenin and GAPDH were detected by immunoblotting. B. Relative densities were quantified using
ImageJ software. Asterisk indicates significant difference when compared to the GFP group (P < 0.05). C. Cells transfected with or without
adenovirus carrying GSK-3β or GFP were subjected to Western blotting analysis for mTOR, p-mTOR, p70S6K1, p-p70S6K1, HIF-1α and
GAPDH expression. The protein levels from three independent experiments are quantified and presented as mean ± SD. Asterisk indicates
significant difference when compared to the control (P < 0.05). (Continued)

www.impactjournals.com/oncotarget
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Figure 2: (Continued) Overexpression of GSK-3β attenuated β-catenin and mTOR/p70S6K1 activation in human
glioma cells. D. and E. Cells transfected with or without adenovirus carrying GSK-3β or GFP were subjected to Western blotting analysis
for mTOR, p-mTOR, p70S6K1, p-p70S6K1, HIF-1α and GAPDH expression. The protein levels from three independent experiments are
quantified and presented as mean ± SD. Asterisk indicates significant difference when compared to the control (P < 0.05). (Continued)

www.impactjournals.com/oncotarget
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Figure 2: (Continued) Overexpression of GSK-3β attenuated β-catenin and mTOR/p70S6K1 activation in human
glioma cells. F. and G. VEGF mRNA and protein levels were detected by semi-quantitative RT-PCR assay and ELISA assay, respectively.
Asterisks indicate significant difference when compared to the control (P < 0.01).

DISCUSSION

rare numbers of CD31-positive microvessels from GSK3β-expressing group compared with GFP control group,
revealing that GSK-3β overexpression significantly reduced
the formation of tumor microvessels (Figure 4C and 4D). We
also analyzed GSK-3β, p-mTOR, p-p70S6K1 and HIF-1α
expression levels by Western blotting in xenograft tumors
from three groups. As expected, the higher levels of GSK-3β
expression in the xenograft tumors from U87-GSK-3β cells
were correlated with the lower expression levels of p-mTOR,
p-p70S6K1, and HIF-1α (Figure 4E). Similarly, it was
confirmed that VEGF mRNA expression in xenograft tumors
were significantly decreased by GSK-3β overexpression
(Figure 4F). In summary, these results demonstrate that GSK3β overexpression inhibits tumor growth.
www.impactjournals.com/oncotarget

Gliomas are the most common primary brain tumor.
Despite aggressive treatment approaches, glioma is still
hardly curable [1, 2]. Extensive studies have demonstrated
that human glioma exhibits aberrant expression profiles
of Wnt/beta-catenin signaling [24, 25]. GSK-3β is an
important molecule to regulate Wnt/beta-catenin signaling,
and is a key regulator of tumor development [26, 27]. For
example, GSK-3β has been shown to regulate the JNK
pathway, and its inhibition triggers apoptosis in pancreatic
cancer [16]. In bladder cancer, GSK-3β positively
regulates cell proliferation and survival in vitro [28].
To the present, a large number of studies demonstrated
31908
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Figure 3: Overexpression of GSK-3β inhibited tumor angiogenesis in vivo. A. U87 cells were transfected with or without
adenovirus carrying GSK-3β or GFP at 10 MOI. After the cells were cultured for 48 h, aliquots of cells (1.0 × 106 cells, 0.1ml) were mixed
in 1:2 ratio with growth factor-reduced phenol red-free Matrigel, and injected subcutaneously into both flanks of nude mice. After 12
days of implantation, the representative plugs from each group were shown. Scale bar: 5 mm. B. The hemoglobin levels in plugs (n = 10).
* indicates significant difference when compared to that of the GFP group (P < 0.05).

GSK-3β as a potential therapeutic target in ovarian, breast
cancer and bladder cancer [29, 30]. However, the role
and the molecular mechanism of GSK-3β in glioma still
remain to be elucidated.
In order to get an insight into the biological relevance
of GSK-3β in glioma, we did immunohistochemical
stainings and Western blotting analysis of total GSK-3β
and phospho-GSK3β at Ser-9 levels in glioma tissues.
Our study shows that there is a strong expression of total
www.impactjournals.com/oncotarget

GSK-3β in the vast majority of normal and glioma tissues.
However, the expression levels of p-GSK-3β (Ser9) were
much higher in glioma tissues when compared to normal
tissues, and were correlated with higher glioma grades.
These results suggest that the expression levels of phosphoGSK-3β-Ser-9 may serve as a valuable prognostic marker
in glioma. To explore the functional relevance of GSK-3β
in glioma, we utilized U87 cells infected with adenovirues
carrying GSK-3β (Ad-GSK-3β). The functional analysis
31909
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Figure 4: Overexpression of GSK-3β decreased tumor growth in vivo. A. U87 cells were transfected with or without adenovirus

carrying GSK-3β or GFP at 20 MOI. After the cells were cultured for 48 h, 3 × 106 cells were injected into both flanks of nude mice. Representative
tumors 35 days after implantation from each group were shown. (Bar: 5 mm) B. The tumor weight was measured for each xenograft. Asterisks
indicate significant difference when compared to the GFP group (P < 0.05). C. Representative image of CD31-stained sections. (Continued)
www.impactjournals.com/oncotarget
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Figure 4: (Continued) Overexpression of GSK-3β decreased tumor growth in vivo. D. Quantitative analysis of MVD in the

xenograft plugs sections. The graph represents the mean ± SD from five different tumor sections for each group. *indicated significant
difference at p < 0.05. E. The protein levels of mTOR, p-mTOR, p70S6K1, p-p70S6K1 and HIF-1α in tumor tissues were analyzed by
Western blotting. GAPDH was used as internal control. (Continued)

www.impactjournals.com/oncotarget
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Figure 4: (Continued) Overexpression of GSK-3β decreased tumor growth in vivo. F. The mRNA levels of VEGF were
analyzed in tumor tissues by semi-quantitative RT-PCR assay.

reveals that ectopic expression of GSK-3β suppressed
angiogenesis and tumor growth in vivo.
It is reported that GSK3β is able to phosphorylate
β-catenin, thus marking the protein for degradation [27,
31]. The expression levels of β-catenin were higher in
glioma tissues compared to the normal tissues, and were
decreased following ectopic expression of GSK-3β in U87
and U251 cells. Therefore, the Wnt/β-catenin signaling
pathway may be involved in the process of glioma
development. Moreover, in the present study, changes in
mTOR/p70S6K1 signaling pathway occurred in U87 and
U251 glioma cells following GSK-3β overexpression,
suggesting that this signaling pathway may play
an important role in the GSK-3β-inhibited glioma
development events. It is currently unknown whether there
is cross-talk between the β-catenin and mTOR cascades
in this regard or if they work independently to strengthen
development. Further investigations are needed to reveal
resolve the relationship between these two signaling
pathways in the context of GSK-3β-inhibited glioma
development.
The mTOR/p70S6k1 signaling pathway is known
to be involved in regulation of HIF-1α stability [32].
VEGF is a key proangiogenic activator which can be
induced at transcriptional level by HIF-1α, and well
known to play an important role in tumor growth and
angiogenesis. Our previous studies revealed that high
expression of VEGF defines carcinomas with more tumor
growth and angiogenesis and poor prognosis. In this study,
overexpression of GSK-3β dramatically down regulates
HIF-1α protein expression as well as VEGF mRNA
levels, Thus, HIF-1α/VEGF pathway may be involved in
www.impactjournals.com/oncotarget

transmitting the biological effects of GSK-3β- inhibited
tumor growth and angiogenesis.
In conclusion, our current study demonstrates
that p-GSK-3β (Ser9) levels are positively related with
higher glioma grades; ectopic expression of GSK-3β is
sufficient to inhibit angiogenesis and tumor growth; we
further identify Wnt/β-catenin and mTOR/p70S6K1/HIF1a/VEGF pathways are involved in GSK-3β-inhibited
angiogenesis and tumor growth. Taken together, these
findings suggest that p-GSK-3β (Ser9) may be a useful
biomarker for glioma development, and provide new
information for using GSK-3β-based diagnostics and/or
potential therapeutic target for glioma treatments in the
future.

MATERIALS AND METHODS
Cell culture and reagents
Human glioma cell lines U87 and U251 (American
Type Culture Collection, Manassas, VA, USA) were
cultured in DMEM supplemented with 2 mmol/L
l-glutamine, 10% fetal bovine serum, 100 units/mL
penicillin, and 100 mg/mL streptomycin, 5% CO2 at 37°C.
Antibodies against GSK-3β, phospho-GSK-3β (Ser9),
β-catenin, AKT, phospho-AKT (Ser473), p70S6K1,
phospho-p70S6K1, mTOR, phospho-mTOR, β-Tubulin
were obtained from Cell Signaling (Beverly, MA, USA).
HIF-1α was from BD Biosciences (Franklin Lakes, NJ,
USA), and GAPDH was purchased from KangCheng
Biotech (Shanghai, China), while antibody against CD31
was supplied by Abcam (Cambridge, UK).
31912
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Tissue samples

Immunoblotting

Tissues were obtained from the first affiliated
hospital of Nanjing Medical University, Nanjing, China.
Total 9 human normal brain tissues and 90 human
glioma tissues were obtained as paraffin-embedded
formalin-fixed blocks. Fresh 5 normal brain tissues
and 33 glioma specimens were collected immediately
after the surgical removal, and snap-frozen in liquid
nitrogen. All patients were provided written informed
consent, and the experimental procedures were approved
by the Institutional Review Board of Nanjing Medical
University. For all of the cases, the pathological diagnosis
and grading were confirmed by two experienced
pathologists in accordance to the principles of World
Health Organization Classification. Types of tissues used
are listed in Table I and II.

Tissues and cells were lysed on ice for 30 min in
RIPA buffer (100 mM Tris, 150 mM NaCl, 1% Triton, 1%
deoxycholic acid, 0.1% SDS, 1 mM EDTA, and 2 mM NaF)
supplemented with 1 mM sodium vanadate, 2 mM leupeptin,
2 mM aprotinin, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 mM DTT, and 2 mM pepstatin A. The supernatant
was collected after centrifugation at 12,000 rpm/min for 15
min, and protein concentration was determined using protein
assay reagent from Bio-Rad (Hercules, CA, USA). Proteins
were electrophoretically separated by SDS-PAGE and
transferred to nitrocellulose (Trans-Blot Transfer Medium,
Bio-Rad). Membranes were blocked with 5% nonfat dry
milk in PBS containing 0.05% Tween 20, and incubated
with specific antibodies. Protein bands were detected
by incubation with horse radish peroxidase-conjugated
antibodies (Cell signaling), and visualized through enhanced
chemiluminescence reagent (Thermo Fisher).

Tissue microarray and immunohistochemistry
Two separated cores taken from paraffin-embedded
specimens of 90 glioma cases and 9 normal brain tissues
were used to construct tissue microarrays. Slides and
sections of the glioma tissues were stained with GSK3β (1:50 dilution) and phospho-GSK-3β (Ser9) (1:100
dilution) antibodies (Cell Signaling, MA, USA),
and then detected by EnVision DAB kit from Dako
(Carpinteria, CA, USA). Staining intensity levels were
independently scored by two observers. Average staining
scores were determined for tissue cores of each case.
Histopathologic diagnosis was examined independently
by immunohistochemical analysis to reduce bias in
scoring staining intensity. Staining intensity is graded
on a 0–3 scales, on which 0 indicated no staining, 1
indicated weak, 2 indicated moderate, 3 indicated the
most intense.

Reverse transcription–PCR (RT–PCR)
Total RNAs were extracted using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instruction. Two micrograms of total
RNAs were used for cDNA synthesis using PrimeScript
RT Master kit (TaKaRa, Dalian, China). Reverse
transcription-PCR (RT-PCR) analysis was performed
using the cDNAs as the template. PCR was amplified for
less than 30 cycles. Levels of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were used as the internal control.
Primers for the PCR analysis were as follows: VEGF,
5′-TCGGGCCTCCGAAACCATGA-3′ (sense), and
5′-CCTGGTGAGAGATCTGGTTC-3′ (antisense); and
GAPDH, 5′-CCACCCATGGCAAATTCCATGGCA-3′
(sense) and 5′-TCTAGACGGCAGGTCAGGTCCACC-3′
(antisense).

Adenovirus preparation and transduction
efficiency

ELISA assay
Capture ELISA was performed using a human
VEGF ELISA kit according to the manufacturer’s
instruction (R&D Systems). Optical densities were read at
405 nm, and the rate of VEGF secretion was calculated as
previously described [19].

The GSK-3β cDNA was sub-cloned into pAdtrackCMV shuttle vector. The resulting plasmid pAdtrackCMV-GSK-3β was linearized with Pme I followed by
homologous recombination with backbone plasmid
pAdEasy-1 in BJ5183 cells to generate recombinant
adenovirus plasmid pAd-GSK-3β (Ad-GSK-3β). The
DNA of identified Ad-GSK-3β was digested with Pac
I, and transfected into 293A cells by lipofectaminemediated method to package recombinant adenovirus.
The titre of the Ad-GSK-3β was measured with the
aid of green fluorescence protein (GFP) expression
after multiplication and purification. In general, the
cell infection was dose-dependent in the range of 5–20
MOI. More than 80% of infected cells were obtained at
10 MOI for U87 and U251 cells after 72 h; thus cells
were infected at 10 MOI from the studies as described
in Figures 2–4.
www.impactjournals.com/oncotarget

Angiogenesis and tumor growth assay
The 4-week-old male nude mice [BALB/cA-nu
(nu/nu)] were purchased from Shanghai Experimental
Animal Center (Chinese Academy of Sciences, China),
maintained in pathogen-free conditions, and sustained
with standard diets. All studies were approved by the
Institutional Committee on Animal Care of Nanjing
Medical University. For angiogenesis assay in nude male
mice, animals were randomly divided into two groups
(n = 5). U87 cells were trypsinized, and suspended in
31913
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serum-free medium (5 × 107 cells/ml). Aliquots of cells
(5 × 106 cells) were mixed with 0.2 ml growth factorreduced phenolred-free Matrigel (BD Biosciences, MA,
USA), and injected subcutaneously into both flanks of
BALB/cA-nude mice. The Matrigel plugs were removed
from the mice 9 days after the implantation, and surrounding
tissues were trimmed. The plugs were photographed and
weighed, and immersed immediately into lysis buffer
(1 mM EDTA and 5 mM phosphate, pH 8), and incubated
at 4°C for 24 h. Hemoglobin content levels were measured
using a Drabkin’s reagent kit (Sigma-Aldrich, St Louis,
MO) based on the manufacturer’s instruction.
For tumor growth assay, animals were randomly
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